Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:56:32 EDT Tue 07 May 2024
Enter Symbol
or Name
USA
CA



News for U:RIGL from 2023-05-08 to 2024-05-07 - 27 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-30 08:05U:RIGLNews ReleaseRigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
2024-04-10 16:30U:RIGLNews ReleaseRigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-04-04 08:05U:RIGLNews ReleaseRigel Announces Publication of Data on REZLIDHIA(TM) (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
2024-03-12 08:05U:RIGLNews ReleaseRigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
2024-03-05 16:01U:RIGLNews ReleaseRigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-02-27 08:05U:RIGLNews ReleaseRigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
2024-02-22 07:50U:RIGLNews ReleaseRigel Pharmaceuticals Acquires U.S. Rights to GAVRETO ‚ ®
2024-01-08 08:05U:RIGLNews ReleaseRigel Pharmaceuticals Provides Business Update
2024-01-05 16:30U:RIGLNews ReleaseRigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-01-04 08:05U:RIGLNews ReleaseRigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma
2024-01-03 08:05U:RIGLNews ReleaseRigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-08 08:05U:RIGLNews ReleaseRigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA ‚ ® (Olutasidenib) in AML and Other Cancers
2023-11-07 16:01U:RIGLNews ReleaseRigel Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-11-06 08:05U:RIGLNews ReleaseRigel to Present at the Jefferies London Healthcare Conference
2023-11-02 09:27U:RIGLNews ReleaseRigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition
2023-10-31 08:05U:RIGLNews ReleaseRigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update
2023-10-11 08:05U:RIGLNews ReleaseRigel Announces Presentation at the Upcoming IDWeek 2023
2023-10-06 16:30U:RIGLNews ReleaseRigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-09-20 08:05U:RIGLNews ReleaseRigel to Present at the 2023 Cantor Global Healthcare Conference
2023-08-30 08:05U:RIGLNews ReleaseRigel to Participate in Upcoming September Investor Conferences
2023-08-01 16:01U:RIGLNews ReleaseRigel Reports Second Quarter 2023 Financial Results and Provides Business Update
2023-07-25 08:00U:RIGLNews ReleaseRigel Announces Conference Call and Webcast to Report Second Quarter 2023 Financial Results and Business Update
2023-07-05 16:30U:RIGLNews ReleaseRigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-06-07 08:05U:RIGLNews ReleaseRigel Announces Presentation of Data from Analysis of REZLIDHIA ‚ ® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML
2023-06-06 08:05U:RIGLNews ReleaseRigel Announces Second REZLIDHIA ‚ ® (Olutasidenib) Publication in Blood Advances
2023-06-01 08:05U:RIGLNews ReleaseRigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual Meeting
2023-05-31 08:05U:RIGLNews ReleaseRigel to Present at the Jefferies 2023 Global Healthcare Conference